Definitive Contract 75N93022C00038

This $600,000 firm fixed price contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Adjuvax LLC of Birmingham, Alabama. The contract is being performed under SBIR Topic 106 to develop adjuvant mimics in support of the NIH and CDC's missions. The solicitation sought proposals for Small Business Innovation Research contracts across numerous technical topics aligned with improving public health. This award is set aside for total...

This is a Phase I Small Business Innovation Research (SBIR) contract awarded by the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases to Teichos Laboratories, LLC, a small business located in West Lafayette, IN. The $300,000 firm fixed price contract is for research on a novel TLR2 agonist-aluminum combination adjuvant to improve the quality and duration of the immune response. This SBIR contract was awarded under a solicitation that sought innovative...

This is a $3,000,000 firm fixed-price Small Business Innovation Research (SBIR) Phase II contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Adjuvax LLC, a small disadvantaged and minority-owned business located in Birmingham, Alabama. The contract supports research and development under SBIR Topic 130, which focuses on discovering and down-selecting vaccine adjuvants for infectious and...

This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases awards Inimmune Corporation $1.99 million to develop a Synthetic Adjuvant System. The contract is a result of the agency's SBIR Phase II solicitation seeking proposals for research and development to advance NIH and CDC missions, including alternatives to cell culture materials and cancer immunotherapy manufacturing. Placed in...

This definitive contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Celdara Medical of Lebanon, New Hampshire. With a value of $599,977, the firm fixed price contract supports research under Solicitation Number NIH-CDC-SBIR-2019 in adjuvant development for vaccines against infectious or immune-mediated diseases. Specifically, the prime contractor will conduct work requested under Topic 081 of the solicitation, which sought small...

This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases (HHS-NIH-NIAID) is valued at $600,000 to Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals, for work in Boston, MA from September 2020 through August 2022. The contract was awarded under the Small Business Innovation Research (SBIR) program's total small business set-aside solicitation seeking proposals on topics...

This is a $598,808 firm fixed price Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Inimmune Corp. The contract is for research on adjuvant discovery for vaccines and for autoimmune and allergic diseases. Inimmune Corp is a biotechnology company with expertise in synthetic chemistry, drug formulation, and pharmaceutical manufacturing. They have received...

The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $375,000 firm fixed price purchase order to Advanced Bioadjuvants, LLC of Omaha, Nebraska. The three-year contract, running from September 2021 through September 2024, provides a non-exclusive license to Advanced Bioadjuvants' Adjuplex adjuvant technology. This will allow the National Institute of Allergy and Infectious Diseases to manufacture cGMP grade...

The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $300,000 definitive contract to Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals, as part of the Small Business Innovation Research Program Phase I Action. The contract is a firm fixed price award with a period of performance from July 5, 2022 through November 30, 2023 to be performed in Canton, Massachusetts. The award is set aside for...

The Department of Health and Human Services' National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded a $599,980 firm fixed price contract to Tendel Therapies, Inc., a small business, for research and development services related to genetic adjuvants to promote durable anti-influenza stem antibodies in older adults. This contract was awarded under the NIH and Centers for Disease Control and Prevention's Small Business Innovation Research (SBIR) program,...